Tags

Type your tag names separated by a space and hit enter

Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS).
BMC Cancer. 2007 Jun 14; 7:100.BC

Abstract

BACKGROUND

The planned nationwide implementation of mammography screening 2007 in Germany will increase the occurrence of mammographically detected breast abnormalities. These abnormalities are normally evaluated by minimal invasive core biopsy. To minimize false positive and false negative histological findings, quality assurance of the pathological evaluation of the biopsies is essential. Various guidelines for quality assurance in breast cancer diagnosis recommend applying the B-classification for histopathological categorization. However, to date there are only few studies that reported results about reliability and validity of B-classification. Therefore, objectives of our study are to determine the inter- and intraobserver variability (reliability study) and construct and predictive validity (validity study) of core biopsy evaluation of breast abnormalities. This paper describes the design and objectives of the DIOS Study.

METHODS/DESIGN

All consecutive asymptomatic and symptomatic women with breast imaging abnormalities who are referred to the University Hospital of Halle for core breast biopsy over a period of 24 months are eligible. According to the sample size calculation we need 800 women for the study. All patients in the study population underwent clinical and radiological examination. Core biopsy is performed by stereotactic-, ultrasound- or magnetic resonance (MR) guided automated gun method or vacuum assisted method. The histopathologic agreement (intra- and interobserver) of pathologists and the histopathologic validity will be evaluated. Two reference standards are implemented, a reference pathologist and in case of suspicious or malignant findings the histopathologic result of excision biopsy. Furthermore, a self administrated questionnaire which contains questions about potential risk factors of breast cancer, is sent to the participants approximately two weeks after core biopsy. This enables us to run a case-control-analysis (woman with breast cancer histological verified after excision are defined as cases, woman without malignant breast lesions are defined as controls) to investigate the predictive values of various risk factors on breast cancer risk.

CONCLUSION

The analysis of reliability and validity of the histopathological evaluation of core biopsy specimens of breast abnormalities is intended to provide important information needed for a high quality in breast cancer diagnostic and for planning of treatment strategies.

Authors+Show Affiliations

Clinical Epidemiology Unit, Institute of Medical Epidemiology, Biometry and Informatics, University Halle-Wittenberg, Halle (Saale), Germany. alexander.kluttig@medizin.uni-halle.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17570833

Citation

Kluttig, Alexander, et al. "Reliability and Validity of Needle Biopsy Evaluation of Breast-abnormalities Using the B-categorization--design and Objectives of the Diagnosis Optimisation Study (DIOS)." BMC Cancer, vol. 7, 2007, p. 100.
Kluttig A, Trocchi P, Heinig A, et al. Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS). BMC Cancer. 2007;7:100.
Kluttig, A., Trocchi, P., Heinig, A., Holzhausen, H. J., Taege, C., Hauptmann, S., Boecker, W., Decker, T., Loening, T., Schmidt-Pokrzywniak, A., Thomssen, C., Lantzsch, T., Buchmann, J., & Stang, A. (2007). Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS). BMC Cancer, 7, 100.
Kluttig A, et al. Reliability and Validity of Needle Biopsy Evaluation of Breast-abnormalities Using the B-categorization--design and Objectives of the Diagnosis Optimisation Study (DIOS). BMC Cancer. 2007 Jun 14;7:100. PubMed PMID: 17570833.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS). AU - Kluttig,Alexander, AU - Trocchi,Pietro, AU - Heinig,Anke, AU - Holzhausen,Hans-Juergen, AU - Taege,Christiane, AU - Hauptmann,Steffen, AU - Boecker,Werner, AU - Decker,Thomas, AU - Loening,Thomas, AU - Schmidt-Pokrzywniak,Andrea, AU - Thomssen,Christoph, AU - Lantzsch,Tilmann, AU - Buchmann,Joerg, AU - Stang,Andreas, Y1 - 2007/06/14/ PY - 2007/04/03/received PY - 2007/06/14/accepted PY - 2007/6/16/pubmed PY - 2007/8/10/medline PY - 2007/6/16/entrez SP - 100 EP - 100 JF - BMC cancer JO - BMC Cancer VL - 7 N2 - BACKGROUND: The planned nationwide implementation of mammography screening 2007 in Germany will increase the occurrence of mammographically detected breast abnormalities. These abnormalities are normally evaluated by minimal invasive core biopsy. To minimize false positive and false negative histological findings, quality assurance of the pathological evaluation of the biopsies is essential. Various guidelines for quality assurance in breast cancer diagnosis recommend applying the B-classification for histopathological categorization. However, to date there are only few studies that reported results about reliability and validity of B-classification. Therefore, objectives of our study are to determine the inter- and intraobserver variability (reliability study) and construct and predictive validity (validity study) of core biopsy evaluation of breast abnormalities. This paper describes the design and objectives of the DIOS Study. METHODS/DESIGN: All consecutive asymptomatic and symptomatic women with breast imaging abnormalities who are referred to the University Hospital of Halle for core breast biopsy over a period of 24 months are eligible. According to the sample size calculation we need 800 women for the study. All patients in the study population underwent clinical and radiological examination. Core biopsy is performed by stereotactic-, ultrasound- or magnetic resonance (MR) guided automated gun method or vacuum assisted method. The histopathologic agreement (intra- and interobserver) of pathologists and the histopathologic validity will be evaluated. Two reference standards are implemented, a reference pathologist and in case of suspicious or malignant findings the histopathologic result of excision biopsy. Furthermore, a self administrated questionnaire which contains questions about potential risk factors of breast cancer, is sent to the participants approximately two weeks after core biopsy. This enables us to run a case-control-analysis (woman with breast cancer histological verified after excision are defined as cases, woman without malignant breast lesions are defined as controls) to investigate the predictive values of various risk factors on breast cancer risk. CONCLUSION: The analysis of reliability and validity of the histopathological evaluation of core biopsy specimens of breast abnormalities is intended to provide important information needed for a high quality in breast cancer diagnostic and for planning of treatment strategies. SN - 1471-2407 UR - https://www.unboundmedicine.com/medline/citation/17570833/Reliability_and_validity_of_needle_biopsy_evaluation_of_breast_abnormalities_using_the_B_categorization__design_and_objectives_of_the_Diagnosis_Optimisation_Study__DIOS__ L2 - https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-7-100 DB - PRIME DP - Unbound Medicine ER -